Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View

•This is the first cost-effectiveness analysis of venetoclax in combination with obinutuzumab (VenO) making available the full economic model following Open Science Practices to promote research transparency and reproducibility.•This is the first European cost-effectiveness analysis of VenO considering an extended societal view in scenario analyses including future nonmedical costs and possible drug price changes upon their patent expiry.•VenO for treatment-naïve adult patients with chronic lymphocytic leukemia is cost-effective compared with chlorambucil plus obinutuzumab from a Dutch (extended) societal perspective, and this finding may be used to support decision making in both clinical applications and reimbursement of VenO.